| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is committed to publishing
draft recommendations on new medicines around the time of licensing, with final guidance
within three months of licensing wherever possible. The Department holds regular accountability
meetings with NICE on a range of topics, including capacity issues. NICE delivers
timely guidance on new medicines in the vast majority of cases and expects to continue
to do so.</p><p>Project Orbis has been established to allow participating partners,
including the United Kingdom, to review and approve applications for promising cancer
treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE
and NHS England and NHS Improvement are ensuring an integrated, timely approach to
access new products, including those licensed through Project Orbis. NHS England and
NHS Improvement and NICE have agreed principles to allow potential interim access
ahead of NICE’s guidance where timely guidance is not anticipated, which has supported
early patient access for a number of medicines licensed through Project Orbis.</p>
|
|
